The present invention relates to systems, apparatus and methods for treating dysfunctional bone structures. More particularly, the present invention relates to systems, apparatus and methods for stabilizing dysfunctional sacroiliac (SI) joints
As is well known in the art, the sacroiliac (SI) joint 6 comprises a diarthrodial synovial joint, which, as illustrated in
As further illustrated in
The sacral floor (denoted “21” in
As illustrated in
The apex of the inverted “L” (denoted “29” in
As illustrated in
As is well known in the art, the SI joint further comprises articular cartilage, i.e., hyaline and fibrocartilage, and a strong, extensive ligamentous architecture, which stabilizes the SI joint.
Generally, the articular surfaces of the sacrum 2 and the ilium 4 that define the SI joint 6 comprise cortical bone 8, which is more compact, dense and hard relative to softer trabecular bone 10, which, as further illustrated in
The SI Joint is distinguished from other synovial joints by the atypical articulation of the different articular surfaces of the sacrum and ilium; the articular surface of the sacrum comprising hyaline cartilage and the articular surface of the ilium comprising substantially stronger fibrocartilage.
As is further well known in the art, the primary plane of motion of the SI joint is anterior-posterior along a transverse axis. The terms often employed to describe the relative motion of the sacrum and ilium are nutation, which refers to anterior-inferior movement of the sacrum while the coccyx (denoted “3” in
In most healthy individuals, the SI joint range of motion in flexion-extension is approximately 3°, approximately 1.5° in axial rotation, and approximately 0.8° in lateral bending.
As is well established, the SI joint performs several seminal biomechanical functions. The primary functions of the SI joint are to attenuate loads exerted on the upper body and to distribute the loads to the lower extremities. The SI joint also functions as a shock absorber for loads exerted on spine.
As is also well established, the noted loads and, hence, forces exerted on the SI joint can adversely affect the biomechanical functions of the SI joint, which can, and often will, result in SI joint dysfunction—an often-overlooked musculoskeletal pathology associated with lower back pain.
Indeed, SI joint dysfunction is estimated to be the primary cause of lower back pain in 15-30% of subjects afflicted with such pain. However, lower back pain associated with SI joint dysfunction is suspected to be far more common than most healthcare providers realize, since such pain is often associated with other skeletal and musculoskeletal dysfunctions.
SI joint dysfunction, and pain associated therewith, can be caused by various SI joint abnormalities and/or disorders, including traumatic fracture dislocation of the pelvis, degenerative arthritis, sacroiliitis, i.e., an inflammation or degenerative condition of the sacroiliac joint; osteitis condensans ilii, and other degenerative conditions of the SI joint structures and associated structures.
Various non-surgical methods, such as administration of pharmacological agents, e.g., the corticosteroid prednisone, and surgical methods and devices, i.e., SI joint prostheses, have been developed and employed to treat SI joint dysfunction and the pain associated therewith.
The most common approach employed to treat SI joint dysfunctions (when non-surgical treatments fail to ameliorate pain associated therewith), at present, is SI joint stabilization, i.e., reinforcing or modulating articulation by and between the sacrum and ilium, via surgical intervention.
SI joint stabilization typically comprises surgical placement of a bone structure prosthesis proximate to or in a dysfunctional SI joint and is generally characterized by the direction of access to the dysfunctional SI joint, e.g., lateral.
Although several conventional SI joint stabilization surgical methods and associated bone structure prostheses have effectively ameliorated pain associated with SI joint dysfunction, there remains many disadvantages associated with the conventional surgical methods and associated bone structure prostheses.
A major disadvantage associated with many conventional SI joint stabilization surgical methods is that the surgeon is required to make a substantial incision in and through the skin and tissues of a subject to access the dysfunctional SI joint. Often referred to as “open surgery” methods, these surgical methods have the attendant disadvantages of requiring general anesthesia and often involve increased operative time, pain, hospitalization, and recovery time due to the extensive soft tissue damage. There is also an increased probability of post-surgical complication associated with open surgery methods, such as nosocomial infection.
Minimally-invasive systems and methods for SI joint stabilization have thus been developed to address the noted disadvantages associated with open surgery methods. Although conventional minimally-invasive SI joint stabilization systems and methods, such as the systems and methods disclosed in U.S. Pub. No. 2009/0076551 to Petersen, have garnered some success in relieving pain associated with SI joint dysfunction and have effectively addressed many of the disadvantages associated with open surgery systems and methods, there similarly remains many disadvantages associated with conventional minimally-invasive SI joint stabilization systems and methods.
A major disadvantage associated with many conventional minimally-invasive SI joint stabilization methods is that such methods are difficult to perform and the associated surgical systems often require extensive, system-specific surgical training and experience. Indeed, it has been found that, notwithstanding the level of surgical training and experience that a surgeon may possess, when such conventional minimally-invasive SI joint stabilization systems and methods are employed, there is still a substantial incidence of damage to the lumbosacral neurovascular structures proximate to the SI joint.
A further disadvantage associated with most conventional minimally-invasive SI joint stabilization methods is that the creation of pilot openings in the SI joint are necessary for placement of a SI joint prostheses and proper alignment is often very difficult to achieve. Further, current conventional tooling systems that are employed to create the pilot openings are often complex and difficult to use.
A further disadvantage associated with many conventional minimally-invasive SI joint stabilization systems and methods is that they comprise anterior or lateral approaches to the dysfunctional SI joint and, hence, muscles, e.g., gluteal aponeurotic fascia and gluteus medius, and ligaments are typically disrupted, and nerves and blood vessels are susceptible to damage during placement of a bone structure prosthesis in a dysfunctional SI joint.
Further, some conventional minimally-invasive SI joint stabilization methods are particularly prone to failure due to the structure of SI joint prostheses and/or failure of the prostheses to effectively engage the SI joint structures, e.g., articular surfaces of the sacrum and/or ilium.
Illustrative are the SI joint prostheses disclosed in U.S. Pat. No. 8,951,254 to Mayer, et al.
The SI joint prostheses disclosed in U.S. Pat. No. 8,951,254 comprise polymer coated multi-piece structures and, hence, among other disadvantages, do not possess the necessary structural integrity to effectively stabilize a dysfunction SI joint when implanted therein.
A further disadvantage associated with the SI joint prostheses disclosed in U.S. Pat. No. 8,951,254 is that the polymer coatings are substantially immunogenic and will induce an adverse immune response when the prostheses are implanted in a dysfunctional SI joint. As is well established, the adverse immune response can, and often will, prevent healing and osteogenic processes, e.g., remodeling of damaged osseous tissue and regeneration of new osseous tissue.
It would thus be desirable to provide SI joint stabilization methods, systems and apparatus, which substantially reduce or eliminate the disadvantages associated with conventional SI joint stabilization methods, systems and apparatus.
It is therefore an object of the invention to provide improved SI joint stabilization methods, systems and apparatus, which substantially reduce or eliminate the disadvantages associated with conventional SI joint stabilization methods, systems and apparatus.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems and apparatus, and methods of using same, that facilitate posterior placement of prostheses in and, thereby, effective stabilization of dysfunctional SI joints.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems and apparatus, including prostheses, which, when employed to stabilize dysfunctional SI joints, disrupt less tissue and muscle, and avoid nerves and large blood vessels.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems and apparatus, including prostheses, which effectively ameliorate pain associated with SI joint dysfunction.
It is another object of the invention to provide improved SI joint prostheses that provide secure engagement to SI joint structures.
It is another object of the invention to provide improved SI joint prostheses that possess optimal structural properties to effectively stabilize dysfunctional SI joints.
It is yet another object of the invention to provide improved SI joint prostheses that facilitate remodeling of damaged osseous tissue and regeneration of new osseous tissue and osseous tissue structures.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems and apparatus adapted to create pilot openings in dysfunctional SI joints for placement of SI joint prostheses therein via a minimal incision.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems adapted to create pilot openings in dysfunctional SI joints for placement of SI joint prostheses therein, which provide optimal direct visualization of the bone dislodging member thereof and the pilot opening during and after creation of the pilot openings.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems adapted to create pilot openings in dysfunctional SI joints that comprise means for retracting and collecting bone material, i.e., autograft bone material, directly from the bone dislodging member after creation of pilot openings (and portions thereof) for subsequent formation of an osteogenic composition and/or direct delivery to prostheses.
It is another object of the invention to provide improved minimally-invasive SI joint stabilization systems that readily receive and properly guide SI joint prostheses into dysfunctional SI joints.
The present invention is directed to minimally-invasive methods, systems and apparatus for stabilizing dysfunctional SI joints.
In one embodiment, there is thus provided a minimally-invasive system for stabilizing a dysfunctional SI joint comprising:
In some embodiments of the invention, the drill guide further comprises a plurality of anchor members extending from the base of the drill guide.
In a preferred embodiment, the first drill guide fixation sub-system is operable when the plurality of K-wires is received in the plurality of K-wire lumens in the drill guide and engage the first and second bone structures of the dysfunctional SI joint.
In a preferred embodiment, the second drill guide fixation sub-system is operable when the K-wire pin member is received in the first drill guide lumen of the drill guide insert and engages the first bone structure of the dysfunctional SI joint, and when the K-wire pin member is received in the second drill guide lumen of the drill guide insert and engages the second bone structure of the dysfunctional SI joint.
In a preferred embodiment, the second drill guide fixation sub-system further operable when the temporary fixation pin is received in the first drill guide lumen of the drill guide insert and engages the first bone structure of the dysfunctional SI joint, and when the temporary fixation pin is received in the second drill guide lumen of the drill guide insert and engages the second bone structure of the dysfunctional SI joint
In a preferred embodiment of the invention, the tool assembly is adapted to access the dysfunctional SI joint in a posterior trajectory.
In a preferred embodiment, the bone dislodging member comprises a drill bit.
In a preferred embodiment, the drill bit comprises a plurality of graduated markings reflecting a first depth of the drill bit into the first bone structure when the first portion of the pilot SI joint opening is the created in the first bone structure and a second depth of the drill bit into the second bone structure when the second portion of the pilot SI joint opening is the created in the second bone structure.
In a preferred embodiment, the graduated markings are directly visible when the first portion of the pilot SI joint opening is created in the first bone structure with the drill bit and when the second portion of the pilot SI joint opening is created in the second bone structure with the drill bit.
In a preferred embodiment, the SI joint prosthesis comprises a first elongated section, a second elongated section, and a bridge section disposed between and connected to the first and second elongated sections,
In some embodiments, the SI joint prosthesis comprises a hollow structure.
In some embodiments, the bridge section comprises a hollow or open structure.
In some embodiments, the bridge section comprises a plurality of apertures and/or slots.
Further features and advantages will become apparent from the following and more particular description of the preferred embodiments of the invention, as illustrated in the accompanying drawings, and in which like referenced characters generally refer to the same parts or elements throughout the views, and in which:
Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified systems, apparatus, structures or methods as such may, of course, vary. Thus, although a number of systems, apparatus, structures and methods similar or equivalent to those described herein can be used in the practice of the present invention, the preferred systems, apparatus, structures and methods are described herein.
It is also to be understood that, although the present invention is described and illustrated in connection with sacroiliac (SI) joint stabilization, fixation and fusion procedures, the invention is not limited to such procedures. According to the invention, the systems, apparatus and methods of the invention can also be employed to stabilize and/or fuse other articulating bone structures, including, without limitation, vertebrae, tarsal bones and the like.
It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only and is not intended to be limiting.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one having ordinary skill in the art to which the invention pertains.
Further, all publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “an incision” includes two or more incisions and the like.
Further, ranges can be expressed herein as from “about” or “approximately” one particular value, and/or to “about” or “approximately” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about” or “approximately”, it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” or “approximately” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “approximately 10” is also disclosed. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “10” is disclosed then “less than or equal to 10” as well as “greater than or equal to 10” is also disclosed.
The terms “bone” and “bone structure” are used interchangeably herein, and mean and include any skeletal member or structure that comprises osseous tissue. The terms “bone” and “bone structure” thus mean and include complete and partial skeletal members or bone structures, including articulating and non-articulating bone structures, (e.g., vertebrae, sacrum, ilium, femur, etc.) and portions thereof.
The terms “sacroiliac joint”, “SI joint”, “sacroiliac junction” and “SI junction” are used interchangeably herein, and mean and include any region proximate to articulating regions of the sacrum and ilium bone structures and, hence, a junction between and defined by sacrum and ilium bone structures. The terms “sacroiliac joint” and “SI joint” thus mean and include a “bone” and “bone structure”.
The term “dysfunctional” as used in connection with a bone structure, means and includes a physiological abnormality, disorder or impairment of a bone structure. The term “dysfunctional” as used in connection with a SI joint thus means and includes, without limitation, a traumatic fracture dislocation of the pelvis, degenerative arthritis, sacroiliitis, i.e., an inflammation or degenerative condition of the SI joint; osteitis condensans ilii, and other degenerative conditions of SI joint bone structures.
The terms “fusion” and “arthrodesis” are used interchangeably herein in connection with bone structures, and mean and include partial or complete immobilization of adjacent bone structures.
The term “stabilization”, as used herein, means and includes reinforcing bone structures or sections thereof, e.g., modulating motion of adjacent articular bone structures; particularly, the sacrum and ilium bone structures. The term “stabilization”, thus, in some instances, means and includes fusion and arthrodesis of adjacent bone structures.
The term “prosthesis”, as used herein in connection with bone structures, means and includes a system or apparatus configured and adapted to stabilize bone structures. The term “prosthesis” thus includes a system or apparatus adapted to modulate motion of articulating bone structures; particularly, sacrum and ilium bone structures.
The term “inferior-posterior”, as used herein in connection with the trajectory of a single-member and multi-member bone structure prosthesis of the invention to a SI joint, means a posterior trajectory to a SI joint through the axial and sagittal planes of the ilium and sacrum bone structures and lower than the dorsal recess of the joint.
The term “transfixed”, as used herein in connection with the single-member and multi-member bone structure prostheses of the invention, means engagement of the bone structure prostheses to the ilium and sacrum bone structures, and the interface or joint therebetween.
The term “biodegradable”, as used herein, means the ability of a material; particularly, a polymer or adhesive, to breakdown and be absorbed within the physiological environment of a SI joint and/or a structure associated therewith, including sacrum and ilium bone structures, by one or more physical, chemical, or cellular processes.
Biodegradable polymers, according to the invention, thus include, without limitation, polylactide polymers (PLA), copolymers of lactic and glycolic acids, including poly(lactic-co-glycolic) acid (PLGA) and poly(ε-caprolactone-co-L-lactic) acid (PCL-LA); glycine/PLA co-polymers, polyethylene oxide (PEO)/PLA block copolymers, acetylated polyvinyl alcohol (PVA)/polycaprolactone copolymers, poly(glycerol sebacate) (PGS) and its derivatives, including poly(glycerol-co-sebacate acrylate) (PGSA); poly(polyol sebacate) (PPS), poly(xylitol sebacate) (PXS), poly(xylitol glutamate sebacate) (PXGS), hydroxybutyrate-hydroxyvalerate copolymers, polyesters such as, but not limited to, aspartic acid and different aliphatic diols; poly(alkylene tartrates) and their copolymers with polyurethanes, polyglutamates with various ester contents and with chemically or enzymatically degradable bonds, other biodegradable nonpeptidic polyamides, amino acid polymers, polyanhydride drug carriers such as, but not limited to, poly(sebacic acid) (PSA); aliphatic-aromatic homopolymers, and poly(anhydride-co-imides), poly(phosphoesters) by matrix or pendant delivery systems, poly(phosphazenes), poly(iminocarbonate), crosslinked poly(ortho ester), hydroxylated polyester-urethanes, or the like.
Biodegradable adhesives, according to the invention, thus include, without limitation, poly(glycerol-co-sebacate acrylate) (PGSA), poly(L-glutamic acid)-based compositions, poly(γ-glutamic acid)-based compositions, poly(alkyl cyano acrylate)-based compositions, polyacrylic acid-based compositions, including polyacrylic acid crosslinked with pentaerythritol and/or allyl sucrose, polyacrylic acid crosslinked with divinyl glycol, and combinations thereof; fibrin-based compositions, collagen-based compositions, including collagen/poly(L-glutamic acid) compositions; albumin-based compositions, including BioGlue® (comprises purified bovine serum albumin (BSA) and glutaraldehyde); cyanoacrylate compositions, including butyl-2-cyanoacrylate adhesives (e.g., Indermil®, Histoacryl®, Histoacryl® Blue, and LiquiBand®) and octyl-2-cyanoacrylate adhesives (e.g., Dermabond®, SurgiSeal™, LiquiBand® Flex, and OctylSeal); poly(ethylene glycol) (PEG) based compositions, including FocalSeal®, Progel™, Duraseal™, DuraSeal™ Xact, Coseal® and ReSure Sealant; polysaccharide-based compositions, polypeptide-based compositions, and combinations thereof.
The term “osteogenic composition”, as used herein, means and includes an agent or composition that induces or modulates an osteogenic physiological or biological process, or cellular activity, e.g., induces proliferation, and/or growth and/or remodeling and/or regeneration of bone or osseous tissue.
The term “osteogenic composition” thus means and includes, without limitation, the following osteogenic materials and compositions comprising same: demineralized bone matrix, autograft bone material, allograft bone material, xenograft bone material, polymethyl-methacrylate, calcium-based bone material, including hydroxyapatite (HA) and tricalcium phosphate; and combinations or mixtures thereof.
The term “osteogenic composition” also means and includes, without limitation, the following polymer materials and compositions comprising same: poly(glycerol sebacate) (PGS), poly(glycerol-co-sebacate) acrylate (PGSA) and co-polymers, such as poly(glycerol sebacate)-co-poly(ethylene glycol) (PGS-PEG); and/or composites thereof, e.g., PGS-hydroxyapatite (HA) composites and PGS-poly(ε-caprolactone) (PGS-PCL) composites.
The term “osteogenic composition” also means and includes, without limitation, acellular extracellular matrix (ECM) derived from mammalian tissue sources.
The term “osteogenic composition” thus means and includes, without limitation, acellular ECM derived from bone or osseous tissue, small intestine submucosa (SIS), epithelium of mesodermal origin, i.e., mesothelial tissue, placental tissue, omentum tissue, and combinations thereof.
The terms “biologically active agent” and “biologically active composition” are used interchangeably herein, and mean and include agent or composition that induces or modulates a physiological or biological process, or cellular activity, e.g., induces proliferation, and/or growth and/or regeneration of tissue, including osseous tissue.
The terms “biologically active agent” and “biologically active composition”, as used herein, thus include agents and compositions that can be varied in kind or amount to provide a therapeutic level effective to mediate the formation or healing of osseous tissue, cartilage and connective tissue, e.g., tendons and ligaments. The term “biologically active composition”, in some instances, thus means and includes an “osteogenic composition.”
The terms “biologically active agent” and “biologically active composition” thus mean and include, without limitation, the following bone morphogenic proteins (BMPs) and compositions comprising same: BMP-1, BMP2a, BMP2b, BMP3, BMP4, BMP5, BMP6, BMP7 (also referred to as osteogenic protein 1 (OP-1)), and BMP8a.
The terms “biologically active agent” and “biologically active composition” also mean and include, without limitation, the following biological agents and compositions comprising same: platelet derived growth factor (PDGF), an insulin-like growth factor (IGF), including IGF-1 and IGF-2; basic fibroblast growth factor (bFGF) (also referred to as FGF2), a transforming growth factor-β (TGF-β), including, TGF-β1 and TGF-β2; a growth hormone (GH), parathyroid hormone (PTH, including PTH1-34), transforming growth factor-α (TGF-α), granulocyte/macrophage colony stimulating factor (GM-CSF), epidermal growth factor (EGF), growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), angiogenin, angiopoietin-1, del-1, follistatin, granulocyte colony-stimulating factor (G-CSF), hepatocyte growth factor/scatter factor (HGF/SF), interleukin-8 (IL-8), interleukin-10 (IL-10), leptin, midkine, placental growth factor, platelet-derived endothelial cell growth factor (PD-ECGF), platelet-derived growth factor-BB (PDGF-BB), pleiotrophin (PTN), progranulin, proliferin, a matrix metalloproteinase (MMP), angiopoietin 1 (ang1), angiopoietin 2 (ang2), and delta-like ligand 4 (DLL4).
The terms “biologically active agent” and “biologically active composition” also mean and include, without limitation, the following cells and compositions comprising same: bone marrow-derived progenitor cells, bone marrow stromal cells (BMSCs), osteoprogenitor cells, osteoblasts, osteocytes, osteoclasts, committed or partially committed cells from the osteogenic or chondrogenic lineage, hematopoietic stem cells, chondrocytes, chondrogenic progenitor cells (CPCs), mesenchymal stem cells (MSCs), and embryonic stem cells.
The terms “pharmacological agent” and “active agent” are used interchangeably herein, and mean and include an agent, drug, compound, composition or mixture thereof, including its formulation, which provides some therapeutic, often beneficial, effect. This includes any physiologically or pharmacologically active substance (or composition comprising same) that produces a localized or systemic effect or effects in animals, including warm blooded mammals.
The terms “pharmacological agent” and “active agent” thus mean and include, without limitation, the following osteoinductive agents and compositions comprising same: icaritin, tumor necrosis factor alpha (TNF-α) inhibitors, including etanercept and infliximab; disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate and hydroxychloroquine; antibiotics, anti-viral agents, steroidal anti-inflammatories, non-steroidal anti-inflammatories, anti-thrombotic agents, including anti-coagulants and anti-platelet agents; and vasodilating agents.
The terms “pharmacological agent” and “active agent” further mean and include, without limitation, the following antibiotics and compositions comprising same: penicillin, carboxypenicillins, such as ticarcillin; tetracyclines, such as minocycline; gentamicin, vancomycin, ciprofloxacin, amikacin, aminoglycosides, cephalosporins, clindamycin, erythromycin, fluoroquinolones, macrolides, azolides, metronidazole, trimethoprim-sulfamethoxazole, polymyxin B, oxytetracycline, tobramycin, cefazolin, and rifampin.
The terms “anti-inflammatory” and “anti-inflammatory agent” are also used interchangeably herein, and mean and include a “pharmacological agent”, which, when a therapeutically effective amount is administered to a subject, prevents or treats bodily tissue inflammation, i.e., the protective tissue response to injury or destruction of tissues, which serves to destroy, dilute, or wall off both the injurious agent and the injured tissues.
Anti-inflammatory agents thus include, without limitation, dexamethasone, betamethasone, prednisone, prednisolone, methylprednisolone sodium succinate, methylprednisolone, cortisone, ketorolac, diclofenac, and ibuprofen.
The term “pharmacological composition”, as used herein, means and includes a composition comprising a “pharmacological agent” and “active agent”.
The term “therapeutically effective”, as used herein, means that the amount of the “pharmacological agent” and/or “pharmacological composition” and/or “biologically active agent” and/or “biologically active composition” administered is of sufficient quantity to induce a physiological reaction, preferably, a positive or desirable physiological reaction in a subject.
The terms “patient” and “subject” are used interchangeably herein, and mean and include warm blooded mammals, humans and primates; avians; domestic household or farm animals, such as cats, dogs, sheep, goats, cattle, horses and pigs; laboratory animals, such as mice, rats and guinea pigs; fish; reptiles; zoo and wild animals; and the like.
The terms “one embodiment”, “one aspect”, and “an embodiment” and “an aspect”, as used herein, means that a particular feature, structure, or characteristic described in connection with the embodiment may be included in at least one embodiment and not that any particular embodiment is required to have a particular feature, structure or characteristic described herein unless set forth in the claim.
The phrase “in one embodiment” or similar phrases employed herein do not limit the inclusion of a particular element of the invention to a single embodiment. The element may thus be included in other, or all embodiments discussed herein.
The term “substantially”, as used herein, means and includes the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result to function as indicated. For example, an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context, such that enclosing nearly all the length of a lumen would be substantially enclosed, even if the distal end of the structure enclosing the lumen had a slit or channel formed along a portion thereof.
Use of the term “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, structure which is “substantially free of” a bottom would either completely lack a bottom or so nearly completely lack a bottom that the effect would be effectively the same as if it completely lacked a bottom.
The term “comprise” and variations of the term, such as “comprising” and “comprises,” means “including, but not limited to” and is not intended to exclude, for example, other components, elements or steps.
The following disclosure is provided to further explain in an enabling fashion the best modes of performing one or more embodiments of the present invention. The disclosure is further offered to enhance the understanding and appreciation for the inventive principles and advantages thereof, rather than to limit in any manner the invention. The invention is defined solely by the appended claims, including any amendments made during the pendency of this application, and all equivalents of those claims as issued.
As indicated above, the present invention is directed to minimally-invasive systems, apparatus and methods for stabilizing dysfunctional SI joints.
As also indicated above, although the present invention is described and illustrated in connection with sacroiliac (SI) joint stabilization, fixation and fusion procedures, the invention is not limited to such procedures. According to the invention, the systems, apparatus and methods of the invention can also be employed to stabilize and/or fuse other articulating bone structures, including, without limitation, vertebrae, tarsal bones, and the like.
In some embodiments of the invention, there are thus provided SI joint stabilizing apparatus, referred to hereinafter as “SI joint stabilization prostheses”, that are configured and adapted to stabilize dysfunctional SI joints. The SI joint prostheses are also configured to be implanted in the dysfunctional SI joint via a minimally-invasive system and, hence, minimally-invasively.
As discussed in detail herein, the minimally-invasive systems of the invention (also referred to herein as “minimally-invasive SI joint stabilization systems”) are configured and adapted to advance the SI joint prostheses into dysfunctional SI joints in a posterior trajectory, more preferably, an inferior-posterior trajectory, such as illustrated in
As indicated above, SI joint stabilization (and, hence, treatment), including minimally-invasive SI joint stabilization, typically comprises surgical placement of a bone structure prosthesis proximate to or in a dysfunctional SI joint via anterior or lateral trajectories.
From the perspective of
More recently, a posterior trajectory has been employed to advance a bone structure prosthesis proximate to and in a dysfunctional SI joint.
Referring now to
Referring now to
As indicated above, a major disadvantage associated with many conventional anterior and lateral trajectories of a bone structure prosthesis to a dysfunctional SI joint is that muscles and ligaments are typically disrupted and often damaged. Nerves and blood vessels are also susceptible to damage during such SI joint stabilization methods.
In contrast, posterior delivery; particularly, inferior-posterior delivery, of the SI joint prostheses of the invention to a dysfunctional SI joint is much less invasive. Indeed, less tissue and fewer muscles are disrupted, and nerves and large blood vessels are avoided. The SI joint prostheses are also transfixed to optimal regions of cortical bone proximate a dysfunctional SI joint and, thereby, provide superior arthrodesis of the dysfunctional SI joint.
In a preferred embodiment of the invention, the SI joint stabilization systems of the invention generally comprise (i) a tool assembly configured and adapted to access the target dysfunctional SI joint via a posterior approach and create at least one pre-determined opening in the dysfunctional SI joint (referred to herein after as a “pilot SI joint opening”), (ii) a SI joint prosthesis configured and adapted to be inserted into the pilot SI joint opening created by the tool assembly, and (iii) a prosthesis deployment assembly configured and adapted to engage the SI joint prosthesis and advance the SI joint prosthesis into the dysfunctional SI joint.
In a preferred embodiment of the invention, the tool assembly comprises an elongated guide pin (referred to as a “guide probe” in Co-pending U.S. application Ser. No. 17/463,779) and a drill guide assembly.
Referring now to
As discussed in detail below, the guide pin 400 is sized and configured to be positioned in a dysfunctional SI joint and, when positioned therein, function as (i) a guide for the drill guide assembly, i.e. drill guide thereof, and, thereby, positioning of the pilot SI joint opening(s) created by the drill guide assembly, (ii) a landmark for the SI joint prosthesis to be disposed in the dysfunctional SI joint, and (iii) in some embodiments, a guide for the prosthesis deployment assembly and, hence, SI joint prosthesis engaged thereto into the pilot SI joint opening created by the drill guide assembly and, thereby, positioning of the SI joint prosthesis in the dysfunctional SI joint.
As illustrated in
According to the invention, the guide pin markings 410 can comprise various distinguishable surface markings, symbols, lines and/or structural patterns and arrangements, which preferably are readily detectable and, hence, readable via a conventional image capture apparatus, such as a fluoroscope and radiography system.
As illustrated in
As illustrated in
As further illustrated in
Referring now to
According to the invention, the drill guide assembly 500a is configured and adapted to create pre-determined pilot SI joint openings in a SI joint; particularly, a dysfunctional SI joint, to accommodate placement of a SI joint prosthesis of the invention therein.
As illustrated in
In a preferred embodiment of the invention, the bone dislodging apparatus preferably comprises a conventional drill bit 501a, which, as illustrated in
As discussed in detail in Co-pending U.S. application Ser. Nos. 17/463,779 and 17/972,785, and illustrated in
As further illustrated in
As further illustrated in
In a preferred embodiment, as additionally shown in
According to the invention, the threaded holes 505a, 505b are sized and configured to receive the threaded end 514 of the access sleeve handle 510a, discussed below.
Referring now to
As illustrated in
As further illustrated in
As illustrated in
As illustrated in
As set forth in Co-pending U.S. application Ser. No. 17/463,779, according to the invention, the drill bit 501a (and drill bit 501b shown in
As illustrated in
In a preferred embodiment, the drill guide medial lumen 526 is sized and configured to receive and guide the guide pin 400 of the invention.
According to the invention, the drill guide internal lumens 524a, 524b and drill guide medial lumen 526 can also be sized and configured to receive various other suitable instruments, such as surgical scopes, center punches, location pins, drill probes and drill stop assemblies, to facilitate the creation of a pilot SI joint opening.
Referring back to
Referring now to
As illustrated in
Referring now to
As illustrated in
As illustrated in
As illustrated in
In a preferred embodiment, the drill guide medial lumen 527 is similarly sized and configured to receive and guide the guide pin 400 of the invention.
According to the invention, the drill guide lumens 525a, 525b and drill guide medial lumen 527 can similarly also be sized and configured to receive various other suitable instruments, such as surgical scopes, center punches, location pins, drill probes, and drill stop assemblies, to facilitate the creation of a pilot SI joint opening.
As illustrated in
As illustrated in
As further illustrated in
As illustrated in
As further illustrated in
Referring now to
As illustrated in
As further illustrated in
In a preferred embodiment, the graduated markings 513 are spaced approximately 10 mm apart and, by virtue of unique configuration of the drill guide 520b and the location of the graduated markings 513, can be directly visualized and, hence, read during creation of pilot SI joint openings with the drill bit 501b.
The graduated markings 513 are also readily detectable and, hence, readable via a conventional image capture apparatus, such as a fluoroscopy and radiography system.
Referring now to
As further illustrated in
To abate premature wear of the graduated markings 513 and, hence, compromised detection and readability of the markings 513 when the drill bit 501b is repeatedly advanced into and through bone structures, the graduated markings 513 are preferably positioned on a flat region 518 on the proximal end region 503d of the drill bit 501b, whereby the graduated markings 513 are inset relative to the outer periphery of the proximal end region 503d of the drill bit 501b.
Referring now to
As illustrated in
As further illustrated in
Referring now to
As illustrated in
As further illustrated in
According to the invention, the drill guide assembly 500b provides several advantages over drill guide 500a. Among the advantages are the following:
Referring now to
As illustrated in
In some embodiments, the drill guide assembly 500c further comprises K-wire pin member 550, which is shown in
As illustrated in
As discussed in detail below, in some embodiments, the temporary fixation pin 530c is employed as a bone tamp to provide a guide recess to position or guide a bone dislodging member of the invention into a bone structure and abate undesired trajectories of the bone dislodging member.
As illustrated in
As illustrated in
As illustrated in
As also illustrated in
As illustrated in
As illustrated in
Referring now to
As illustrated in
As further illustrated in
As additionally illustrated in
According to the invention, the guide member lumen 827 of the elongated guide member 800a can similarly also be sized and configured to receive various other suitable instruments, such as surgical scopes, center punches, location pins, drill probes, and drill stop assemblies, to facilitate the creation of a pilot SI joint opening.
As illustrated in
As further illustrated in
In a preferred embodiment, the first and second lobe portions 564a, 564b of the prosthesis internal access opening 560 of the drill guide 520c are similarly sized and configured to receive (i) a bone dislodging apparatus of the invention; particularly, drill bit 501b, and (ii) drill alignment pin 530a, temporary fixation pins 530b, 530c, and, if employed, K-wire pin member 550.
In a preferred embodiment, the opposed concave regions 810 of the elongated guide member 800a are sized and configured to allow slidable translation of a bone dislodging apparatus of the invention, e.g., drill bit 501c, and drill alignment pin 530a, temporary fixation pins 530b, 530c, and/or K-wire pin member 550 into and through the first and second lobe portions 564a, 564b when the elongated guide member 800a is positioned in the medial portion 562 of the prosthesis internal access opening 560.
As will readily be appreciated by one having ordinary skill in the art, the first and second lobe portions 564a, 564b and medial portion 562 can also readily accommodate various other suitable instruments, such as surgical scopes, center punches, location pins, drill probes, and drill stop assemblies.
Referring back to
According to the invention, the threaded holes 511a, 511b are similarly sized and configured to receive the threaded end of a handle, such as the threaded end 514 of access sleeve handle 510a shown in
As illustrated in
According to the invention, the drill guide assembly 500c also provides all the aforementioned seminal advantages provided by drill guide assembly 500b.
Referring now to
As illustrated in
As discussed in detail below, the drill guide 520d also comprises elongated guide member 800a illustrated in
As illustrated in
As illustrated in
As illustrated in
As further illustrated in
As illustrated in
The extended region 819 of the elongated guide member 800a is also sized and configured to slidably translate into the guide member receiving slot 565a disposed on the proximal end 521a of the drill guide 520d.
Referring back to
In a preferred embodiment, the opposed concave regions 810 of the elongated guide member 800a are similarly sized and configured to allow slidable translation of a bone dislodging apparatus of the invention, e.g., drill bit 501b, and drill alignment pin 530a, temporary fixation pins 530b, 530c, and/or K-wire pin member 550 into and through the first and second lobe portions 564a, 564b when the elongated guide member 800a is positioned in the medial portion 562 of the prosthesis internal access opening 560.
Referring now to
As illustrated in
According to the invention, the drill guide assembly 500d similarly provides all the aforementioned seminal advantages provided by drill guide assemblies 500b and 500c.
Referring now to
As illustrated in
In some embodiments of the invention, the drill guide also comprises the drill guide anchors 531 of drill guide 520d illustrated in
As illustrated in
As illustrated in
As further illustrated in
As also illustrated in
As indicated above and illustrated in
Referring now to
As illustrated in
As illustrated in
In a preferred embodiment, the K-wire seat 822 has a predetermined depth (into the K-wire driver 820) to facilitate a desired advancement of the K-wires 509 into bone structures.
Referring now to
As illustrated in
As further illustrated in
In a preferred embodiment, the drill guide lumens 525c, 525d are sized and configured to receive (i) a bone dislodging apparatus of the invention; preferably, drill bit 501b, and (ii) the drill alignment pin 530a, temporary fixation pins 530b, 530c, and, if employed, K-wire pin member 550.
As also illustrated in
According to the invention, the drill guide medial lumen 527 can similarly be sized and configured to receive various other suitable instruments, such as surgical scopes, center punches, location pins, drill probes, and drill stop assemblies, to facilitate the creation of a pilot SI joint opening.
As further illustrated in
According to the invention, the drill guide assembly 500e similarly provides all the aforementioned seminal advantages provided by drill guide assemblies 500b, 500c and 500d, including:
The drill guide assembly 500e also provides consistent, optimal guidance of (i) the bone dislodging apparatus of the invention; particularly, drill bit 501b, during creation of the SI joint openings in bone structures; particularly, SI joint bone structures, therewith, and (ii) the SI joint prostheses of the invention into the pilot SI joint openings.
As indicated above, in a preferred embodiment, the drill guide assemblies 500a, 500b, 500c, 500d and 500e are configured and adapted to create pilot SI joint openings in SI joint bone structures to accommodate placement of a SI joint prosthesis of the invention therein.
Referring now to
As illustrated in
As further illustrated in
In some embodiments, the pilot SI joint opening cross-sectional shape (i.e., pilot SI joint opening 100) is defined in part by at least one noncircular cross-sectional shaped region (denoted “105”) in the noted plane.
As additionally illustrated in
The three-dimensional pilot SI joint opening 100, i.e., cross-sectional shape thereof, also comprises a longitudinal axis (denoted “LA2”) in the plane that intersects the sacrum 2 and ilium 4 and an initial pilot SI joint opening length along the axis LA2.
Referring now to
According to the invention, the sacrum and ilium guide portions 203, 204 can comprise various configurations, e.g., cross-sectional shapes, and sizes to, as discussed in detail below, accommodate insertion of defined regions of a prosthesis of the invention therein and transition of the sacrum and ilium guide portions 203, 204 from pilot or first configurations and sizes to expanded second configurations and sizes when the prosthesis is inserted therein.
According to the invention, the sacrum and ilium guide portions 203, 204 can also be disposed at various locations in the sacrum 2 and ilium 4.
In some embodiments, the sacrum and ilium guide portions 203, 204 are disposed in the sacrum 2 and ilium 4 such that at least a portion of the sacrum and ilium guide portions 203, 204 extends into the cortical bone 8 of the SI joint structures, i.e., sacrum 2 and ilium 4, as shown in
In some embodiments, the sacrum and ilium guide portions 203, 204 are solely disposed in the sacrum 2 and ilium 4, as shown in
As illustrated in
As further illustrated in
In a preferred embodiment, the sacrum and ilium guide portions 203, 204 of the pilot SI joint opening 200 are disposed on a plane that similarly intersects the sacrum 2 and ilium 4.
According to the invention, various suitable SI joint prostheses, such as the prostheses illustrated in
Referring now to
As illustrated in
As further illustrated in
As set forth in Applicant's Co-Pending U.S. application Ser. Nos. 17/463,779, 17/468,811 and 18/107,563, the SI joint prosthesis 70a can comprise any suitable length from the proximal ends 79a to the distal ends 79b of the partially cylindrical sections 76a, 76b.
In some embodiments, the SI joint prosthesis 70a (and 70b discussed below) comprises a length in the range of 20-50 mm, more preferably, a length in the range of 30-40 mm.
As illustrated in
As illustrated in
The second partially cylindrical surface region 77b similarly preferably comprises a partially cylindrical surface region shape that corresponds to at least a portion of the first lobe region 103 of the pilot SI joint opening 100 and/or the sacrum guide portion 203 of the pilot SI joint opening 200, or the second lobe region 104 of the pilot SI joint opening 100 and/or the ilium guide portion 204 of the pilot SI joint opening 200, again depending on the entry position of the prosthesis 70a into the pilot SI joint openings 100, 200.
As illustrated in
In some embodiments of the invention, the taper region 82 comprises two angled regions that intersect at a central point 83, i.e., pointed proximate the mid-region of the bridge section 78, such as shown in
In some embodiments, the taper region 82 comprises a single angled or sloped region defining a plane that intersects the plane defined by the bottom surface of the SI joint prosthesis 70a, i.e., wedge shaped or bevel configuration.
In a preferred embodiment, the distal ends 79b of the first and second elongated partially cylindrical sections 76a, 76b also comprise tapered regions 84a, 84b, which facilitate (i) insertion of the distal ends 79b of the first and second elongated partially cylindrical sections 76a, 76b into the first and second lobe regions 103, 104 of the pilot SI joint opening 100 and/or the sacrum and ilium guide portions 203, 204 of the pilot SI joint opening 200, and (ii) as discussed in detail below, in some embodiments, transition of the pilot SI joint opening 100 from a first configuration and size (and, hence, cross-sectional area, i.e., A2-1 shown in
As illustrated in
As illustrated in
In a preferred embodiment, the internal prosthesis engagement member lumens 86a, 86b of the SI joint prosthesis 70a are sized and configured to receive the prosthesis guide pins 606 of the prosthesis deployment assemblies 600a, 600b, discussed below, and the prosthesis engagement rod 700 of the prosthesis deployment assemblies 600a, 600b.
As illustrated in
In a preferred embodiment, the internal prosthesis engagement lumens 86a, 86b are also configured to receive agents and compositions that further facilitate adhesion of the SI joint prosthesis 70a to the pilot SI openings 100, 200 of the invention and, thereby, sacrum and/or ilium, and bone material, e.g., autograft bone, and the aforementioned biologically active agents and compositions, including osteogenic agents and compositions, and pharmacological agents and compositions that facilitate osseous or bone tissue ingrowth into the SI joint prosthesis 70a and healing of the SI joint bone structures.
Referring back to
Referring now to
In some embodiments of the invention, the bridge section comprises a hollow structure, e.g., further comprises at least one internal passageway that is adapted to also receive the bone material, agents and compositions referenced above.
In a preferred embodiment, the bone material, agents and compositions referenced above are adapted to extrude through the slots 90 and apertures 92a, 92b of the SI joint prostheses 70a, 70b when the SI joint prostheses 70a, 70b are inserted in a pilot SI joint opening (i.e., pilot SI joint openings 100 or 200), to, as indicated above, (i) further facilitate adhesion of the SI joint prostheses 70a, 70b to the pilot SI openings 100, 200 of the invention and, thereby, sacrum and/or ilium, and (ii) facilitate osseous or bone tissue ingrowth into the SI joint prostheses 70a, 70b and healing of the SI joint bone structures.
Referring now to
As set forth in Co-pending U.S. application Ser. Nos. 17/463,779 and 17/468,811, according to one embodiment of the invention, the length of the prosthesis cross-sectional shape PCCS along longitudinal axis LA1 is greater than the length of the pilot SI joint opening 100 illustrated in
As further illustrated in
As further illustrated in
In a preferred embodiment of the invention, to achieve sufficient expansion of the pilot SI joint openings 100, 200 when the SI joint prostheses 70a, 70b are inserted therein, preferably, the cross-sectional areas of the regions defined by the first and second elongated partially cylindrical sections 76a, 76b of the SI joint prostheses 70a, 70b are at least 0.05% greater than the cross-sectional areas defined by the first and second lobe regions 103, 104 of the pilot SI joint opening 100, and the cross-sectional areas defined by the sacrum and ilium guide portions 203, 204 of pilot SI joint opening 200.
In some embodiments of the invention, the cross-sectional areas of the regions defined by the first and second elongated partially cylindrical sections 76a, 76b of the SI joint prostheses 70a, 70b are substantially equal to or slightly smaller, e.g., <0.05%, than the cross-sectional areas defined by the first and second lobe regions 103, 104 of the pilot SI joint opening 100, and the cross-sectional areas defined by the sacrum and ilium guide portions 203, 204 of pilot SI joint opening 200.
According to the invention, the SI joint prostheses 70a, 70b can comprise various biocompatible materials, including metals and metal alloys, such as titanium, stainless-steel, cobalt-chromium alloys and nickel-titanium alloys, and various biocompatible polymers, including, without limitation, reinforced polymers, such as carbon fiber reinforced polymers and metal-framed polymers.
The SI joint prostheses 70a, 70b can additionally comprise a porous structure to facilitate (i) adhesion of the prostheses 70a, 70b to post-prosthesis insertion SI joint openings of the invention and, thereby, to SI joint bone structures, i.e., sacrum and ilium bone structures, and (ii) bone or osseous tissue ingrowth into the prostheses 70a, 70b.
The SI joint prostheses 70a, 70b can further comprise various exterior surface textures and roughness to facilitate or enhance engagement of the prosthesis to post-prosthesis insertion SI joint openings, and, thereby, to SI joint bone structures, i.e., sacrum and ilium bone structures, and/or maintain engagement thereto and positioning therein.
According to the invention the SI joint prostheses 70a, 70b can further comprise an outer coating.
In some embodiments, the outer coating comprises one of the aforementioned osteogenic compositions.
In some embodiments, the osteogenic composition comprises a demineralized bone matrix, autograft bone material, allograft bone material, xenograft bone material, polymethyl-methacrylate or calcium-based bone material.
In some embodiments, the osteogenic composition comprises a bone morphogenic protein (BMP).
In some embodiments, the BMP comprises BMP-1, BMP2a, BMP2b, BMP3, BMP4, BMP5, BMP6, BMP7, or BMP8a.
In some embodiments, the outer coating comprises one of the aforementioned biologically active agents.
In some embodiments, the biologically active agent comprises a basic fibroblast growth factor (bFGF), a transforming growth factor-β (TGF-β), a vascular endothelial growth factor (VEGF), a platelet derived growth factor (PDGF), an insulin-like growth factor (IGF), an epidermal growth factor (EGF), or a growth and differentiation factor-5 (GDF-5).
In some embodiments, the outer coating comprises one of the aforementioned pharmacological agents.
In some embodiments of the invention, the outer coating comprises a biocompatible adhesive composition.
According to the invention, suitable adhesive compositions include, without limitation, poly(L-glutamic acid)-based compositions, poly(γ-glutamic acid)-based compositions, poly(alkyl cyano acrylate)-based compositions, polyacrylic acid-based compositions, including polyacrylic acid crosslinked with pentaerythritol and/or allyl sucrose, polyacrylic acid crosslinked with divinyl glycol and combinations thereof; fibrin-based compositions, collagen-based compositions, including collagen and poly(L-glutamic acid) compositions; albumin-based compositions, including BioGlue® (comprises purified bovine serum albumin (BSA) and glutaraldehyde); cyanoacrylate compositions, including butyl-2-cyanoacrylate adhesives (e.g., Indermil®, Histoacryl®, Histoacryl® Blue, and LiquiBand®) and octyl-2-cyanoacrylate adhesives (e.g., Dermabond®, SurgiSeal™, LiquiBand® Flex, and OctylSeal); poly(ethylene glycol) (PEG) based compositions, including FocalSeal®, Progel™, Duraseal™, DuraSeal™ Xact, Coseal® and ReSure Sealant; polysaccharide-based compositions, polypeptide-based compositions, and radiation curable materials, such as poly(glycerol-co-sebacate) acrylate (PGSA), discussed below.
In some embodiments, the outer coating comprises one of the aforementioned polymers and/or compositions comprising same.
In some embodiments of the invention, the polymer comprises poly(glycerol sebacate) (PGS) or a derivative thereof, including, without limitation, poly(glycerol-co-sebacate) acrylate (PGSA) and PGS co-polymers, such as poly(glycerol sebacate)-co-poly(ethylene glycol) (PGS-PEG); and/or composites thereof, e.g., PGS-hydroxyapatite (HA) composites and PGS-poly(ε-caprolactone) (PGS-PCL) composites, and compositions comprising same.
Exemplar PGS coated SI joint prostheses are described in detail in Applicant's Co-Pending U.S. application Ser. Nos. 17/463,779, 17/468,811, and 17/469,132, which are expressly incorporated herein in its entirety.
As set forth in Co-Pending U.S. application Ser. Nos. 17/463,779, 17/468,811, and 17/469,132, PGS and derivatives thereof possess a unique property of inducing remodeling of damaged osseous or bone tissue, such as at pilot SI joint openings, and, hence, healing of the associated bone structures when disposed proximate thereto.
As further set forth in Co-Pending U.S. application Ser. Nos. 17/463,779, 17/468,811, and 17/469,132, in some embodiments, the PGS based outer coatings comprise a degree of esterification in the range of ˜76%-83%, whereby the PGS exhibits adhesive properties, which will enhance engagement of prostheses 70a, 70b to the post-prosthesis insertion SI joint openings 300, 400 and, thereby, to the SI joint bone structures, i.e., sacrum and ilium bone structures.
As additionally set forth in Co-pending U.S. application Ser. Nos. 17/463,779, 17/468,811, and 17/469,132, PGS and its derivatives; particularly, PGSA are also excellent platforms for delivery and, hence, administration of biologically active agents and pharmacological agents to mammalian tissue, including osseous or bone tissue. Thus, in some embodiments of the invention, the PGS outer coatings and PGS and PGSA based compositions further comprise one or more of the aforementioned biologically active or pharmacological agents.
As indicated above, in a preferred embodiment of the invention, the tool assemblies of the invention further comprise a bone harvesting assembly adapted to extract and contain bone material from the bone dislodging apparatus, i.e., drill bit, after creating the SI joint opening or a portion thereof.
Referring now to
As illustrated in
As illustrated in
As further illustrated in
As further illustrated in
As additionally illustrated in
As illustrated in
To secure the bone harvesting members 904a, 904b in the closed configuration illustrated in
As illustrated in
In a preferred embodiment, the securing arm 922 is connected proximate to the first edge region 905a of bone harvesting member 904a and the engagement member 926 is connected proximate the first edge region 905c of bone harvesting member 904b.
As further illustrated in
According to the invention, the securing arm 922 can also be adapted to flex from the closed configuration to the noted open configuration and vice versa when engaged to the bone harvesting member 904a. Such arm flexure can be provided and/or achieved via the securing arm composition, i.e., comprising a flexible material, or securing arm configuration.
As illustrated in
In a preferred embodiment, the securing arm 922 further comprises a retainer flap 926 disposed on the distal end 925 of the engagement member receiving slot 924 that is sized and configured to releasably engage the engagement member 930 when the engagement member 930 is positioned in the receiving slot 924 and the securing arm 922 is in the closed configuration.
Referring now to
In a preferred embodiment, the bone extracting tabs 912 are sized, positioned and configured to extract bone material from the drill bit flute (or flutes) when the bone collection assembly 900 is in the closed configuration and the bone retraction sleeve 902 is translated linearly over the drill bit.
According to the invention, the bone extracting tabs 912 can be disposed at any position on the drill bit seats 908a, 908b, e.g., mid-regions, proximal end regions, distal end regions, combinations thereof, etc.
As indicated above, one or both of the drill bit seats 908a, 908b can also comprise a plurality of bone extracting tabs 912.
In an alternative embodiment, one or both of the drill bit seats 908a, 908b comprises a brush apparatus that is similarly sized and adapted to seat in the drill bit flute(s) and extract bone material from the drill bit flute(s) when the bone retraction sleeve 902 is translated linearly over the drill bit.
As indicated above and illustrated in
As illustrated in
According to the invention, the handle 940 facilitates manual linear translation of the bone retraction sleeve 902 over a drill bit and rotation thereof during the linear translation, and, hence, bone material extraction from the drill bit.
In some envisioned embodiments, powered translation means are employed to induce linear translation of the bone retraction sleeve 902 over the drill bit to extract bone material therefrom.
According to the invention, various means and apparatus can be employed to harvest or capture the bone material that is extracted from the drill bit by the bone retraction sleeve 902.
Referring again to
As illustrated in
Referring now to
As illustrated in
As illustrated in
As further illustrated in
According to the invention, the bone extracting tabs 1006 are also sized and configured to extract bone material from the drill bit, i.e., flute (or flutes) thereof, when the tong member 1002 is contracted in a direction denoted by Arrow “A”, whereby the tong member 1002 is in a closed configuration, and the drill bit, i.e., drill bit 501a and/or 501b is rotated, whereby the tong member 1002 and, hence, bone material extracting tabs 1006 translate linearly down the drill bit in a helical fashion.
Referring now to
As illustrated in
As further illustrated in
As further illustrated in
According to the invention, when bone material is extracted from a bone dislodging member, i.e., drill bit, and deposited into the bone material receiving region 1030 of the prosthesis holder 1020, the extracted bone material is delivered into the internal lumens of the SI joint prosthesis, e.g., internal lumens 86a, 86b of SI joint prostheses 70a, 70b, when seated in the prosthesis seat 1032.
To facilitate compaction of the bone material into the SI joint prosthesis, the harvesting assembly further comprises a bone tamp or compactor 1040.
Referring now to
In a preferred embodiment, the distal end 1042b of the bone tamp 1040 is sized and configured to be received in the internal lumens of the SI joint prostheses to, as indicated above, compact the bone material delivered thereto.
In some embodiments of the invention, the bone harvesting assembly further comprises a bone material delivery apparatus, which, as discussed in detail below, is configured and adapted to delivery bone material extracted from the bone dislodging apparatus directly into the internal lumens of SI joint prostheses 70a, 70b.
Referring now to
As illustrated in
As illustrated in
As further illustrated in
As further illustrated in
In a preferred embodiment, the length of the elongated body region (and, hence, bone delivery lumens 1056a, 1056b) is sufficient to receive and, hence, deliver a sufficient amount of bone material to SI joint prostheses 70a, 70b to substantially fill the internal lumens 86a, 86b of SI joint prostheses 70a, 70b.
As further illustrated in
In a preferred embodiment, the first and second prosthesis engagement regions 1062a, 1062b are sized and configured to be received into the internal lumens of the SI joint prosthesis, e.g., internal lumens 86a, 86b of SI joint prostheses 70a, 70b, and, hence, deliver bone material extracted from the bone dislodging apparatus directly into the internal lumens 86a, 86b of SI joint prostheses 70a, 70b.
Referring now to
As illustrated in
As illustrated in
As further illustrated in
As illustrated in
As illustrated in
Referring now to
As further illustrated in
Referring back to
Referring now to
As illustrated in
As illustrated in
As illustrated in
In accordance with the one embodiment of the invention, there is thus provided a method of stabilizing a dysfunctional SI joint comprising the following steps:
In some embodiments, the method further comprises the steps of (i) providing a bone harvesting assembly of the invention; preferably, the bone harvesting assembly illustrated in
As indicated above, in a preferred embodiment, when the SI joint prosthesis, i.e., SI joint prosthesis 70a (and, hence, SI joint prosthesis 70b when employed), is advanced into the pilot SI joint opening with the prosthesis deployment assembly 600a, the SI joint prosthesis, i.e., SI joint prosthesis 70a, is disposed at a distance in the range of at least 2.0 mm to 6.0 mm away from the SI joint dorsal recess, more preferably, a distance of at least 3.0 mm away from the SI joint dorsal recess.
In a preferred embodiment, when the SI joint prosthesis, i.e., SI joint prosthesis 70a or 70b, is advanced into the pilot SI joint opening with the prosthesis deployment assembly 600a, the SI joint prosthesis is preferably press-fit in the pilot SI joint opening and induces a transition of the pilot SI joint opening to a larger post-prosthesis insertion SI joint opening.
In a preferred embodiment, a further initial step in the minimally-invasive SI joint stabilization methods of the invention comprises the step of providing an image capture apparatus configured and adapted to capture images of at least the subject's anatomical structure, including the dysfunctional SI joint and the anatomic structure proximate thereto, and the guide pin 400 and SI joint prostheses 70a, 70b during advancement toward and when disposed proximate to the dysfunctional SI joint.
In a preferred embodiment, the image capture apparatus comprises a CT system. However, according to the invention, further suitable image capture apparatus comprise a fluoroscopy system, radiography system, magnetic resonance imaging system, and an ultrasound system.
In a preferred embodiment, after the step of providing the image capture apparatus, and before the step of making an incision in and through tissue of the subject, a further step in the minimally-invasive SI joint stabilization methods comprises capturing images of the subject's anatomical structure with the image capture apparatus to properly align the patient on the surgical table. According to the invention, standard or classic lateral images via CT scans can be employed to ensure proper alignment, i.e., a true prone position, of the patient.
After the step of ensuring proper alignment of the patient, a further initial step in the minimally-invasive SI joint stabilization methods of the invention comprises determining key SI joint landmarks, e.g., dogleg, dorsal recess, etc., preferably, via CT scans, to establish at least a sagittal line, incision (or skin entry) site, and guide pin trajectory and, thereby, prosthesis trajectory into the dysfunctional SI joint.
Since the SI joint comprises a unique shape and does not align with the axis of the spine (i.e., the plane of the SI joint defined by the region between the sacrum and the ilium is not aligned with (or parallel with) the sagittal plane or anteroposterior axis of the spine), as discussed in detail below, in a preferred embodiment, modified anteroposterior (AP) views or images of at least the subject's dysfunctional SI joint, and the guide pin 400 and SI joint prostheses when deployed in the subject's body are acquired via CT scans.
As discussed above, advancement of the guide pin 400 into the dysfunctional SI joint is a critical step in the methods for stabilizing a dysfunctional SI joint. The guide pin 400 ensures (i) proper trajectory of the drill guides of the invention and creation of the pilot SI joint openings, e.g., pilot SI joint opening 100, (ii) proper trajectory of the prosthesis deployment assemblies 600a, 600b and, hence, SI joint prostheses 70a, 70b engaged thereto to and into the pilot SI joint openings and, thereby, accurate and optimal placement of the SI joint prostheses 70a, 70b in the dysfunctional SI joint.
In a preferred embodiment, during the step of advancing the guide pin 400 into the dysfunctional SI joint, a further step in the minimally-invasive SI joint stabilization methods thus comprises capturing images of the guide pin 400 with the image capture apparatus to ensure proper trajectory and placement of the guide pin 400 proximate the dysfunctional SI joint.
As indicated above, since the SI joint comprises a unique shape and does not align with the axis of the spine, in a preferred embodiment, a series modified (or angled) anteroposterior (AP) images of the guide pin 400 and dysfunctional SI joint (and, if necessary, surrounding structures) during advancement of the guide pin 400 toward and, particularly, when disposed proximate to and in the dysfunctional SI joint are preferably acquired via CT scans to ensure proper trajectory and placement of the guide pin 400 proximate the dysfunctional SI joint.
Referring first to
Referring now to
The modified AP view of the dysfunctional SI joint (“SIJ2”) shown in
As indicated above, in a preferred embodiment, the guide pin 400 is advanced into the dysfunctional SI joint to, but no further than, the alar boundary (denoted “AB” in
A CT scan image showing a tangent lateral view of the dysfunctional SI joint (“SIJ2”) also facilitates accurate advancement and, hence, depth of the guide pin 400 in the dysfunctional SI joint (“SIJ2”), as shown in
In a preferred embodiment, during the step of advancing the SI joint prosthesis into the pilot SI joint opening with the prosthesis deployment assemblies 600a, 600b, a further step in the minimally-invasive SI joint stabilization methods comprises capturing images of the SI joint prosthesis with the image capture apparatus to ensure proper placement of the SI joint prostheses 70a, 70b in the dysfunctional SI joint.
In a preferred embodiment, CT scan images showing lateral views of the drill guide assemblies 500a, 500b, 500c, 500d and 500e and the prosthesis deployment assemblies 600a, 600b during advancement of the drill guide assemblies 500a, 500b, 500c, 500d and 500e and prosthesis deployment assemblies 600a, 600b toward and, particularly, when disposed proximate to the dysfunctional SI joint are acquired to ensure proper trajectory of the drill guide assemblies 500a, 500b, 500c, 500d and 500e and the prosthesis deployment assemblies 600a, 600b, such as shown in
In a preferred embodiment, CT scan images showing modified AP and/or trajectory inlet views of the SI joint prosthesis and dysfunctional SI joint (and, if necessary, surrounding structures) during advancement of the SI joint prostheses 70a, 70b toward and, particularly, when disposed proximate to and in the dysfunctional SI joint are also acquired to ensure proper trajectory and placement of the SI joint prosthesis in the dysfunctional SI joint, such as shown in
In some embodiments, after the step of creating the pilot SI joint opening with the drill guide assemblies 500a, 500b, 500c, 500d and 500e, the methods for stabilizing a dysfunctional SI joint further comprise the step of harvesting the dislodged bone material, e.g., cortical bone, trabecular bone, and bone marrow, with one of the aforediscussed bone harvesting assemblies for subsequent use in a biologically active composition of the invention and thereafter delivery to the SI joint prostheses 70a, 70b.
The following example is provided to enable those skilled in the art to more clearly understand and practice the present invention. The example should not be considered as limiting the scope of the invention, but merely as being illustrated as representative thereof.
An adult male, age 42 presented with a traumatic injury proximate the SI joint, resulting in a dysfunctional SI joint and significant pain associated therewith, i.e., a visual analog pain score (VAS) of approximately 8.0.
CT scans were initially performed to determine the full extent of the patient's injury, check for any SI joint abnormalities, and plan the SI joint stabilization procedure, including determining the incision site, guide pin trajectory, and SI joint prosthesis required to stabilize the dysfunctional SI joint.
Before proceeding with the SI joint stabilization procedure, CT scans were also performed to ensure proper alignment of the patient on the surgical table.
The SI joint stabilization procedure was performed in accord with the method that includes the drill guide assembly 500e summarized above. The specifics of the procedure were as follows:
The SI joint prothesis selected and, hence, provided for the stabilization procedure comprised SI joint prosthesis 70a illustrated in
The SI joint prosthesis 70a included an autograft bone material, which was placed in the barrels of the SI joint prosthesis 70a after the prosthesis was implanted in the dysfunctional SI joint.
The initial incision was placed along the lateral lip of the posterior third of the iliac crest to the posterior superior spine, which provided a prosthesis entry point into the dysfunctional SI joint through the posterior ligaments at approximately the S3 level. The trajectory of the SI joint prosthesis was toward the mid-point of the S1 end plate and the sacral promontory.
The pilot SI joint opening was created with the drill guide assembly 500e illustrated in
The pilot SI joint opening, which was similar to pilot SI joint opening 200 described above, was created by drilling a first opening in the sacrum bone structure and a second opening in the ilium bone structure with the drill guide assembly 500e.
After the first opening in the sacrum bone structure and second opening in the ilium bone structure were created with the drill guide assembly 500e, the dislodged bone material, i.e., autograft bone material, was harvested with the bone collection assembly illustrated in
CT scan images of the patient's SI joint six (6) months after the SI joint stabilization procedure reflected (i) secure and proper placement of the SI joint prosthesis in the SI joint, (ii) substantial solid bridging of osseous tissue, and, hence, bone across the SI joint and, (iii) substantial ossification around the SI joint prosthesis.
After a recovery period of fourteen (14) days, the patient reported that the pain had been substantially reduced.
The patient was also subjected to a series of post procedure tests to determine the stability of the SI joint and mobility of the musculoskeletal structures of the pelvic and lumbar regions proximate the SI joint. The results were very favorable. The patient tested positive to the flexion abduction and external rotation (FABER) test. The patient also responded very favorably to Gaenslen, thigh thrust, compression, and distraction tests.
The tests thus confirmed that the post procedure SI joint was stabilized and that the musculoskeletal structures of the pelvic and lumbar regions proximate thereto were restored to a near normal level.
As will readily be appreciated by one having ordinary skill in the art, the present invention provides numerous advantages compared to prior art systems and methods for stabilizing dysfunctional SI joints. Among the advantages are the following:
Without departing from the spirit and scope of this invention, one of ordinary skill can make various changes and modifications to the invention to adapt it to various usages and conditions. As such, these changes and modifications are properly, equitably, and intended to be, within the full range of equivalence of the following claims.
This application is a continuation-in-part of U.S. patent application Ser. No. 17/903,527, filed on Sep. 6, 2022, which is a continuation-in-part of U.S. patent application Ser. No. 17/833,960, filed on Jun. 7, 2022, which is a continuation-in-part of U.S. patent application Ser. No. 17/833,098, filed on Jun. 6, 2022, which is a continuation of U.S. patent application Ser. No. 17/749,199, filed on May 20, 2022, which is a continuation-in-part application of U.S. patent application Ser. No. 17/740,568, filed on May 10, 2022, which is a continuation-in-part application of U.S. patent application Ser. No. 17/463,779, filed on Sep. 1, 2021, which is a continuation-in part of U.S. patent application Ser. No. 13/857,977, filed on Apr. 5, 2013, now U.S. Pat. No. 11,273,042, which is a continuation application of U.S. patent application Ser. No. 13/192,289, filed Jul. 27, 2011, now abandoned, which claims the benefit of U.S. provisional patent application Ser. No. 61/368,233, filed on Jul. 27, 2010.
Number | Date | Country | |
---|---|---|---|
61368233 | Jul 2010 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17833960 | Jun 2022 | US |
Child | 17903527 | US | |
Parent | 17749199 | May 2022 | US |
Child | 17833098 | US | |
Parent | 13192289 | Jul 2011 | US |
Child | 13857977 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17903527 | Sep 2022 | US |
Child | 18240197 | US | |
Parent | 17833098 | Jun 2022 | US |
Child | 17833960 | US | |
Parent | 17740568 | May 2022 | US |
Child | 17749199 | US | |
Parent | 17463779 | Sep 2021 | US |
Child | 17740568 | US | |
Parent | 13857977 | Apr 2013 | US |
Child | 17463779 | US |